Compare Amgen, Inc. (AMGN) vs Celestica Inc (CLS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Celestica Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Celestica Inc trades at $350.04 (market cap $41.29B). The key difference: Amgen, Inc. is far larger — about 4.7× Celestica Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Celestica Inc pays none. Which is the better fit depends on your goals.
| AMGN | CLS | |
|---|---|---|
Market Cap | $196.12B | $41.29B |
Sector | Health | Technology |
52-Week High | $388.16 | $472.40 |
52-Week Low | $271.18 | $156.91 |
Enterprise Value | $241.41B | $41.69B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CLS trades at $359.85, up 1.43% today, with a bullish technical outlook and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust profitability with a 52.45% ROE and 6.95% net margin, supported by positive analyst sentiment and a $440.10 consensus price target. Recent leadership changes and raised revenue guidance to $19 billion highlight growth prospects in AI and cloud infrastructure.
Outlook remains positive driven by AI demand and earnings beats, but high valuation multiples (P/E 43.62) and competitive pressures pose risks. Investors should monitor Q2 2026 results on July 27, 2026, for confirmation of growth trajectory amid margin challenges noted by analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Celestica Inc
Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →
